{
    "nct_id": "NCT04924608",
    "official_title": "A Phase III, Multicentre, International Study With a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)",
    "inclusion_criteria": "* Adults ≥ 18 years at enrollment with diagnosis of NF1 with symptomatic, inoperable PN\n* At least one inoperable target PN measurable by volumetric MRI analysis\n* Chronic target PN pain score documented for minimum period during screening period\n* Stable chronic PN pain medication use at enrollment\n* Adequate organ and marrow function\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Confirmed or suspected malignant glioma or MPNST (low grade glioma, including optic glioma not requiring systemic therapy or radiation therapy are exempt from this exclusion)\n* History of malignancy except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention and of low potential risk for recurrence\n* Clinically significant cardiovascular disease, including inherited coronary disease, acute coronary syndrome within 6 months prior to enrollment, uncontrolled angina, symptomatic heart failure, cardiomyopathy, severe valvular heart disease, abnormal LVEF and uncontrolled hypertension\n* Ophthalmological findings/conditions including intraocular pressure > 21 mmHg, RPED/CSR or RVO\n* Prior exposure to MEK inhibitors",
    "miscellaneous_criteria": "Key"
}